{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:52:33Z","timestamp":1782435153660,"version":"3.54.5"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,6]]},"DOI":"10.7759\/cureus.19308","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T15:11:03Z","timestamp":1636211463000},"source":"Crossref","is-referenced-by-count":12,"title":["Evaluating the Use of Hydroxychloroquine in Treating Patients With Rheumatoid Arthritis"],"prefix":"10.7759","author":[{"given":"Armaan M","family":"Nazir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavya","family":"Koganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marrium S","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bin","family":"Aslam Zahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignarth","family":"Shantha Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Tappiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihan A","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"MedlinePlus. Rheumatoid arthritis. (2020). Accessed: August 10, 2021: https:\/\/medlineplus.gov\/genetics\/condition\/rheumatoid-arthritis\/."},{"key":"ref2","unstructured":"Arthritis Ireland. Rheumatoid arthritis. (2021). Accessed: August 10, 2021: https:\/\/www.arthritisireland.ie\/rheumatoid-arthritis."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32832a2e16","article-title":"Environmental influences on risk for rheumatoid arthritis","volume":"21","author":"Liao KP","year":"2009","unstructured":"Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol. 2009, 21:279-83. 10.1097\/BOR.0b013e32832a2e16","journal-title":"Curr Opin Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/ar761","article-title":"Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1","volume":"5","author":"D'Elia HF","year":"2003","unstructured":"D'Elia HF, Mattsson LA, Ohlsson C, Nordborg E, Carlsten H. Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. Arthritis Res Ther. 2003, 5:R202-9. 10.1186\/ar761","journal-title":"Arthritis Res Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11781017","article-title":"Hydroxychloroquine use and risk of CKD in patients with rheumatoid arthritis","volume":"13","author":"Wu CL","year":"2018","unstructured":"Wu CL, Chang CC, Kor CT, Yang TH, Chiu PF, Tarng DC, Hsu CC. Hydroxychloroquine use and risk of CKD in patients with rheumatoid arthritis. Clin J Am Soc Nephrol. 2018, 13:702-9. 10.2215\/CJN.11781017","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171176","article-title":"Sex-associated treatment differences and their outcomes in rheumatoid arthritis: results from the METEOR register","volume":"45","author":"Bergstra SA","year":"2018","unstructured":"Bergstra SA, Allaart CF, Ramiro S, et al.. Sex-associated treatment differences and their outcomes in rheumatoid arthritis: results from the METEOR register. J Rheumatol. 2018, 45:1361-6. 10.3899\/jrheum.171176","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin YJ","year":"2020","unstructured":"Lin YJ, Anzaghe M, Sch\u00fclke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020, 9:880. 10.3390\/cells9040880","journal-title":"Cells"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key275","article-title":"The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients","volume":"58","author":"Schapink L","year":"2019","unstructured":"Schapink L, van den Ende CH, Gevers LA, van Ede AE, den Broeder AA. The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients. Rheumatology (Oxford). 2019, 58:131-4. 10.1093\/rheumatology\/key275","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13184","article-title":"Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy","volume":"20","author":"Wabe N","year":"2017","unstructured":"Wabe N, Wojciechowski J, Wechalekar MD, et al.. Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy. Int J Rheum Dis. 2017, 20:1447-56. 10.1111\/1756-185X.13184","journal-title":"Int J Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.141234","article-title":"The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study","volume":"70","author":"Klarenbeek NB","year":"2011","unstructured":"Klarenbeek NB, G\u00fcler-Y\u00fcksel M, van der Kooij SM, et al.. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011, 70:1039-46. 10.1136\/ard.2010.141234","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi I","year":"2012","unstructured":"Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012, 42:145-53. 10.1007\/s12016-010-8243-x","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.037333","article-title":"Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?","volume":"64","author":"M\u00e4kinen H","year":"2005","unstructured":"M\u00e4kinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?. Ann Rheum Dis. 2005, 64:1410-3. 10.1136\/ard.2005.037333","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000816","article-title":"Patients with arthralgia and anti-citrullinated peptide antibody positivity on hydroxychloroquine therapy: an update on 2 and 3 years' follow-up data of a pilot study","volume":"25","author":"Merkesdal S","year":"2019","unstructured":"Merkesdal S, Kirchhoff T, Jablonka A, Schmidt RE, K\u00f6hler L. Patients with arthralgia and anti-citrullinated peptide antibody positivity on hydroxychloroquine therapy: an update on 2 and 3 years' follow-up data of a pilot study. J Clin Rheumatol. 2019, 25:311-3. 10.1097\/RHU.0000000000000816","journal-title":"J Clin Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2013.04.005","article-title":"Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study","volume":"39","author":"Diav-Citrin O","year":"2013","unstructured":"Diav-Citrin O, Blyakhman S, Shechtman S, Ornoy A. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol. 2013, 39:58-62. 10.1016\/j.reprotox.2013.04.005","journal-title":"Reprod Toxicol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex378","article-title":"The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies","volume":"57","author":"Schreiber K","year":"2018","unstructured":"Schreiber K, Breen K, Parmar K, Rand JH, Wu XX, Hunt BJ. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology (Oxford). 2018, 57:120-4. 10.1093\/rheumatology\/kex378","journal-title":"Rheumatology (Oxford)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23759","article-title":"Low persistence rates in patients with rheumatoid arthritis treated with triple therapy and adverse drug events associated with sulfasalazine","volume":"71","author":"Erhardt DP","year":"2019","unstructured":"Erhardt DP, Cannon GW, Teng CC, Mikuls TR, Curtis JR, Sauer BC. Low persistence rates in patients with rheumatoid arthritis treated with triple therapy and adverse drug events associated with sulfasalazine. Arthritis Care Res (Hoboken). 2019, 71:1326-35. 10.1002\/acr.23759","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2016.1266029","article-title":"Three out of four disease-modifying anti-rheumatic drug-na\u00efve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12\u00a0months: results from the FIN-ERA cohort","volume":"46","author":"Rannio T","year":"2017","unstructured":"Rannio T, Asikainen J, Hannonen P, et al.. Three out of four disease-modifying anti-rheumatic drug-na\u00efve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12\u00a0months: results from the FIN-ERA cohort. Scand J Rheumatol. 2017, 46:425-31. 10.1080\/03009742.2016.1266029","journal-title":"Scand J Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications","volume":"334","author":"O'Dell JR","year":"1996","unstructured":"O'Dell JR, Haire CE, Erikson N, et al.. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996, 334:1287-91. 10.1056\/NEJM199605163342002","journal-title":"N Engl J Med"},{"key":"ref19","unstructured":"Medscape. Rheumatoid arthritis (RA) clinical presentation. (2021). Accessed: August 11, 2021: https:\/\/emedicine.medscape.com\/article\/331715-clinical#b1."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2021.04.011","article-title":"PRISMA 2020: an update","volume":"35","author":"Swartz MK","year":"2021","unstructured":"Swartz MK. PRISMA 2020: an update. J Pediatr Health Care. 2021, 35:P351. 10.1016\/j.pedhc.2021.04.011","journal-title":"J Pediatr Health Care"},{"key":"ref21","article-title":"Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate","volume":"29","author":"Carmichael SJ","year":"2002","unstructured":"Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol. 2002, 29:2077-83.","journal-title":"J Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq424","article-title":"The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study","volume":"50","author":"Kyburz D","year":"2011","unstructured":"Kyburz D, Gabay C, Michel BA, Finckh A. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology (Oxford). 2011, 50:1106-10. 10.1093\/rheumatology\/keq424","journal-title":"Rheumatology (Oxford)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis","volume":"43","author":"Nell VP","year":"2004","unstructured":"Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004, 43:906-14. 10.1093\/rheumatology\/keh199","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.010298","article-title":"Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis","volume":"63","author":"van Aken J","year":"2004","unstructured":"van Aken J, Lard LR, le Cessie S, Hazes JM, Breedveld FC, Huizinga TW. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis. 2004, 63:274-9. 10.1136\/ard.2003.010298","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#","article-title":"High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors","volume":"44","author":"del Rinc\u00f3n ID","year":"2001","unstructured":"del Rinc\u00f3n ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001, 44:2737-45.","journal-title":"Arthritis Rheum"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(76)90086-2","article-title":"Mortality among arthritics","volume":"29","author":"Monson RR","year":"1976","unstructured":"Monson RR, Hall AP. Mortality among arthritics. J Chronic Dis. 1976, 29:459-67. 10.1016\/0021-9681(76)90086-2","journal-title":"J Chronic Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3109\/03009748209098167","article-title":"Increased mortality in rheumatoid arthritis","volume":"11","author":"Allebeck P","year":"1982","unstructured":"Allebeck P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol. 1982, 11:81-6. 10.3109\/03009748209098167","journal-title":"Scand J Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/23.2.92","article-title":"Cause of death in rheumatoid arthritis","volume":"23","author":"Prior P","year":"1984","unstructured":"Prior P, Symmons DP, Scott DL, Brown R, Hawkins CF. Cause of death in rheumatoid arthritis. Br J Rheumatol. 1984, 23:92-9. 10.1093\/rheumatology\/23.2.92","journal-title":"Br J Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2016.07.006","article-title":"Cardiovascular disease in patients with rheumatoid arthritis","volume":"27","author":"Liao KP","year":"2016","unstructured":"Liao KP. Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med. 2016, 27:136-40. 10.1016\/j.tcm.2016.07.006","journal-title":"Trends Cardiovasc Med"},{"key":"ref30","article-title":"Cardiovascular mortality in women with rheumatoid arthritis","volume":"22","author":"Myllykangas-Luosuj\u00e4rvi R","year":"1995","unstructured":"Myllykangas-Luosuj\u00e4rvi R, Aho K, Kautiainen H, Isom\u00e4ki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol. 1995, 22:1065-7.","journal-title":"J Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.6.374","article-title":"Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis","volume":"56","author":"Munro R","year":"1997","unstructured":"Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis. 1997, 56:374-7. 10.1136\/ard.56.6.374","journal-title":"Ann Rheum Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90345-e","article-title":"Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids","volume":"89","author":"Wallace DJ","year":"1990","unstructured":"Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med. 1990, 89:P322-26. 10.1016\/0002-9343(90)90345-e","journal-title":"Am J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22483","article-title":"Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study","volume":"67","author":"Desai RJ","year":"2015","unstructured":"Desai RJ, Eddings W, Liao KP, Solomon DH, Kim SC. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study. Arthritis Care Res (Hoboken). 2015, 67:457-66. 10.1002\/acr.22483","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000502","article-title":"Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients","volume":"23","author":"Restrepo JF","year":"2017","unstructured":"Restrepo JF, Del Rincon I, Molina E, Battafarano DF, Escalante A. Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients. J Clin Rheumatol. 2017, 23:144-8. 10.1097\/RHU.0000000000000502","journal-title":"J Clin Rheumatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22285","article-title":"Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial","volume":"66","author":"Solomon DH","year":"2014","unstructured":"Solomon DH, Garg R, Lu B, Todd DJ, Mercer E, Norton T, Massarotti E. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken). 2014, 66:1246-51. 10.1002\/acr.22285","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002867","article-title":"Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients","volume":"5","author":"Sharma TS","year":"2016","unstructured":"Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, Bili A. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc. 2016, 5:e002867. 10.1161\/JAHA.115.002867","journal-title":"J Am Heart Assoc"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3596-7","article-title":"Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China","volume":"36","author":"Li C","year":"2017","unstructured":"Li C, Wang XR, Ji HJ, et al.. Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China. Clin Rheumatol. 2017, 36:1023-9. 10.1007\/s10067-017-3596-7","journal-title":"Clin Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.08.010","article-title":"Development of reduced kidney function in rheumatoid arthritis","volume":"63","author":"Hickson LJ","year":"2014","unstructured":"Hickson LJ, Crowson CS, Gabriel SE, McCarthy JT, Matteson EL. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014, 63:206-13. 10.1053\/j.ajkd.2013.08.010","journal-title":"Am J Kidney Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160225","article-title":"Inflammation as a risk of developing chronic kidney disease in rheumatoid arthritis","volume":"11","author":"Kochi M","year":"2016","unstructured":"Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Inflammation as a risk of developing chronic kidney disease in rheumatoid arthritis. PLoS One. 2016, 11:e0160225. 10.1371\/journal.pone.0160225","journal-title":"PLoS One"},{"key":"ref40","article-title":"Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis","volume":"50","author":"Nakano M","year":"1998","unstructured":"Nakano M, Ueno M, Nishi S, et al.. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol. 1998, 50:154-60.","journal-title":"Clin Nephrol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380213","article-title":"Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis","volume":"38","author":"Helin HJ","year":"1995","unstructured":"Helin HJ, Korpela MM, Mustonen JT, Pasternack AI. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum. 1995, 38:242-7. 10.1002\/art.1780380213","journal-title":"Arthritis Rheum"},{"key":"ref42","article-title":"Antimalarial drug induced decrease in creatinine clearance","volume":"22","author":"Landew\u00e9 RB","year":"1995","unstructured":"Landew\u00e9 RB, Vergouwen MS, Goeei The SG, Van Rijthoven AW, Breedveld FC, Dijkmans BA. Antimalarial drug induced decrease in creatinine clearance. J Rheumatol. 1995, 22:34-7.","journal-title":"J Rheumatol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S14257","article-title":"Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the \"flying saucer\" sign)","volume":"4","author":"Chen E","year":"2010","unstructured":"Chen E, Brown DM, Benz MS, Fish RH, Wong TP, Kim RY, Major JC. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the \"flying saucer\" sign). Clin Ophthalmol. 2010, 4:1151-8. 10.2147\/OPTH.S14257","journal-title":"Clin Ophthalmol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2014.10.019","article-title":"Chloroquine and hydroxychloroquine binding to melanin: some possible consequences for pathologies","volume":"1","author":"Schroeder RL","year":"2014","unstructured":"Schroeder RL, Gerber JP. Chloroquine and hydroxychloroquine binding to melanin: some possible consequences for pathologies. Toxicol Rep. 2014, 1:963-8. 10.1016\/j.toxrep.2014.10.019","journal-title":"Toxicol Rep"},{"key":"ref45","article-title":"Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review","volume":"7","author":"Geam\u0103nu (Panc\u0103) A","year":"2014","unstructured":"Geam\u0103nu (Panc\u0103) A, Popa-Cherecheanu A, Marinescu B, Geam\u0103nu C, Voinea L. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review. J Med Life. 2014, 7:322-6.","journal-title":"J Med Life"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.298","article-title":"Hydroxychloroquine retinopathy","volume":"31","author":"Yusuf IH","year":"2017","unstructured":"Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond). 2017, 31:828-45. 10.1038\/eye.2016.298","journal-title":"Eye (Lond)"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0008-0","article-title":"Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy)","volume":"15","author":"Grassmann F","year":"2015","unstructured":"Grassmann F, Bergholz R, M\u00e4ndl J, J\u00e4gle H, Ruether K, Weber BH. Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). BMC Ophthalmol. 2015, 15:18. 10.1186\/s12886-015-0008-0","journal-title":"BMC Ophthalmol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.321","article-title":"Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy","volume":"129","author":"Michaelides M","year":"2011","unstructured":"Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011, 129:30-9. 10.1001\/archophthalmol.2010.321","journal-title":"Arch Ophthalmol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00409-3","article-title":"The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal","volume":"110","author":"Mavrikakis I","year":"2003","unstructured":"Mavrikakis I, Sfikakis PP, Mavrikakis E, et al.. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003, 110:1321-26. 10.1016\/S0161-6420(03)00409-3","journal-title":"Ophthalmology"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.01.014","article-title":"Pericentral hydroxychloroquine retinopathy in Korean patients","volume":"122","author":"Lee DH","year":"2015","unstructured":"Lee DH, Melles RB, Joe SG, et al.. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology. 2015, 122:1252-6. 10.1016\/j.ophtha.2015.01.014","journal-title":"Ophthalmology"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015122","article-title":"Current screening practice in patients under long-term hydroxychloroquine medication in Taiwan: a nationwide population-based cohort study","volume":"98","author":"Yen CY","year":"2019","unstructured":"Yen CY, Lee PH, Yen JC, Chen CC, Hu HY, Tseng PC. Current screening practice in patients under long-term hydroxychloroquine medication in Taiwan: a nationwide population-based cohort study. Medicine (Baltimore). 2019, 98:e15122. 10.1097\/MD.0000000000015122","journal-title":"Medicine (Baltimore)"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-020-01549-4","article-title":"Is optical coherence tomography angiography a useful tool in the screening of hydroxychloroquine retinopathy?","volume":"41","author":"Tarakcioglu HN","year":"2021","unstructured":"Tarakcioglu HN, Ozkaya A, Yigit U. Is optical coherence tomography angiography a useful tool in the screening of hydroxychloroquine retinopathy?. Int Ophthalmol. 2021, 41:27-33. 10.1007\/s10792-020-01549-4","journal-title":"Int Ophthalmol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.112161","article-title":"Spectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquine","volume":"61","author":"Ulviye Y","year":"2013","unstructured":"Ulviye Y, Betul T, Nur TH, Selda C. Spectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquine. Indian J Ophthalmol. 2013, 61:168-71. 10.4103\/0301-4738.112161","journal-title":"Indian J Ophthalmol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.3.522","article-title":"Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases","volume":"32","author":"Eo DR","year":"2017","unstructured":"Eo DR, Lee MG, Ham DI, et al.. Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases. J Korean Med Sci. 2017, 32:522-7. 10.3346\/jkms.2017.32.3.522","journal-title":"J Korean Med Sci"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.018","article-title":"Pericentral retinopathy and racial differences in hydroxychloroquine toxicity","volume":"122","author":"Melles RB","year":"2015","unstructured":"Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology. 2015, 122:110-6. 10.1016\/j.ophtha.2014.07.018","journal-title":"Ophthalmology"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20133","article-title":"Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus","volume":"62","author":"Wolfe F","year":"2010","unstructured":"Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010, 62:775-84. 10.1002\/acr.20133","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles RB","year":"2014","unstructured":"Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014, 132:1453-60. 10.1001\/jamaophthalmol.2014.3459","journal-title":"JAMA Ophthalmol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.1720","article-title":"Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users","volume":"132","author":"Nika M","year":"2014","unstructured":"Nika M, Blachley TS, Edwards P, Lee PP, Stein JD. Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol. 2014, 132:1199-208. 10.1001\/jamaophthalmol.2014.1720","journal-title":"JAMA Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/73787-evaluating-the-use-of-hydroxychloroquine-in-treating-patients-with-rheumatoid-arthritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:09Z","timestamp":1707507189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/73787-evaluating-the-use-of-hydroxychloroquine-in-treating-patients-with-rheumatoid-arthritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":58,"URL":"https:\/\/doi.org\/10.7759\/cureus.19308","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,6]]}}}